Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

@article{Ogasawara2014EfficacyOS,
  title={Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.},
  author={Sadahisa Ogasawara and Tetsuhiro Chiba and Yoshihiko Ooka and Naoya Kanogawa and Tenyu Motoyama and Eiichiro Suzuki and Akinobu Tawada and Fumihiko Kanai and Masaharu Yoshikawa and Osamu Yokosuka},
  journal={Oncology},
  year={2014},
  volume={87 6},
  pages={330-41}
}
OBJECTIVE We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage hepatocellular carcinoma (HCC). METHODS This retrospective study reviewed intermediate-stage HCC patients who underwent the first TACE. Patients were defined as TACE-refractory and divided into two cohorts: (1) patients who switched from TACE to sorafenib and (2) those who continued TACE. We evaluated the patient overall survival (OS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
23 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…